Neoadjuvant/Adjuvant Pembrolizumab Regimen Continues to Show EFS Benefit in High-Risk Early TNBC

The 5-year event-free survival EFS) rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab compared with 72.3% in those who received placebo/chemotherapy plus placebo.

Related Keywords

San Antonio ,Texas ,United States ,Peter Schmid ,Barts Breast Cancer Centre ,Eastern Cooperative Oncology Group ,Centre Of Eand ,Oncology Nursing ,Antonio Breast Cancer ,Cancer Medicine ,Antonio Breast Cancer Symposium ,Event Free Survival ,Pembrolizumab ,Triple Negative Breast Cancer ,High Risk ,Early Stage Triple Negative Breast Cancer ,Ntnbc ,Keynote 522 ,Neoadjuvant Pembrolizumab ,